HOME >> BIOLOGY >> NEWS
Combination Therapy For Brain Tumors Holds Promise For Longer Survival After,,Surgery

Combination Therapy for Brain Tumors Holds Promise for Longer Survival After Surgery Despite advances in neuroimaging and surgery, no major developments in the treatment of malignant brain tumors have been introduced in the past two decades. Right now, surgeons rely on radiation therapy after removal of the tumor to mop up microscopic cancerous cells that could lead to regrowth. Brain tumors, however, are extremely resistant to radiation treatment. Researchers at the University of Pennsylvania Medical Center have now found a way to make brain cancer cells more receptive to radiation treatment --by 60-fold in some cases.

"The goal of our research is to extend the survival of terminally ill patients and give them a better quality of life during that time," says Donald M. O'Rourke, MD, assistant professor of neurosurgery. "Following a diagnosis of brain cancer, median survival of patients is only 12 months with treatment." More than 17,000 new cases of brain cancer are reported each year, according to O'Rourke, and this diagnosis is nearly always fatal.

In a biochemical one-two punch to brain cancer cells, O'Rourke and colleagues inactivated a common cell-surface receptor called the Epidermal Growth Factor Receptor (or erbB for short) to arrest cell growth in human cell lines, which further sensitized the cells to radiation. This approach works in a similar way to Herceptin, the new breast-cancer-fighting drug awaiting FDA approval. Herceptin, a monoclonal antibody therapy, is based on the basic research performed by the laboratory of Mark I. Greene, MD, PhD, at Penn. Both strategies target mutated or overexpressed erbB receptor proteins that allow cancer cells to grow unchecked.

"Depending on which type of cell we used, we achieved between 20 and 60 percent cell death in cancer cells where the erbB receptor was first deactivated, versus zero to 5 percent in radiation-alone controls," reports O'Rourke. These findings were pu
'"/>

Contact: Karen Young Kreeger
kreeger@mail.med.upenn.edu
(215) 614-0290
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related biology news :

1. Combination of gene therapy and gene silencing prevents neurodegenerative disease
2. Combination therapy dramatically improves function after spinal cord injury in rats
3. Combination therapy drives cancer into remission
4. Combination drug therapy drastically reduces multiple coronary heart disease risk factors
5. Combination therapy improves anthrax survival
6. Drug Combination May Prove Effective To Prevent Recurrence Of Hepatitis C After Transplantation
7. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
8. Dangerous Chemical Combination Presents Possible Scenario For Gulf War Illnesses
9. 1st International Conference on Cell Therapy for Cardiovascular Disease
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Braunschweig Prize 2003 for Molecular Cancer Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... ... announced their strategic partnership to offer a full spectrum of digital security goods ... suite of biometric products and the ground-breaking proactive cybersecurity services and products through ...
(Date:4/20/2017)... 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: ... the International Liver Congress ("ILC") 2017 of the European Association ... Amsterdam on the positive effects of PBI-4050 on ... obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of ...
(Date:4/20/2017)... TIKVAH, Israel , April 20, 2017 /PRNewswire/ ... adult stem cell technologies for neurodegenerative diseases, announced today that ... the Alliance for Regenerative Medicine,s (ARM) 5 th Annual ... 2017 at 09:40 EDT in Boston . ... MHSc, Chief Medical Officer & Chief Operating Officer, will participate ...
(Date:4/19/2017)... ... 2017 , ... Optofluidics today announced that it's changing its ... changed focus to making analytical tools for biopharmaceutical quality control. “We are excited ... Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered the ...
Breaking Biology Technology:
Cached News: